mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced  
Phone 01494 818 000
Current Jobs

Sales Specialist
Location: North East

Product Manager
Location: West Yorkshire

Territory Manager - Sports Medicine
Location: M62 Corridor

Regional Business Manager
Location: North East Region

Sales Specialist - PAS
Location: North East

Expert Trainer
Location: Mid UK

Field Sales Coach - Central
Location: Central UK

Senior Brand Manager
Location: Welwyn Garden City

Territory Manager - Sports Medicine
Location: South Central

Sales Specialist - MSS
Location: West Midlands

Centralised Diagnostics Sales Specialist
Location: South and Central London

Medical Advisor
Location: Princes Risborough, Bucks

Training Manager - Renal & Neurology and ELearnin
Location: Maidenhead, Berks

Training Manager - Part-time
Location: Maidenhead

Territory Manager - Sports Medicine
Location: West Scotland

Depression linked to increased Alzheimer's risk

Posted on 16/06/2009 in Industry related health news

People suffering from memory problems who are depressed are more likely to develop Alzheimer's disease, new research claims.

The study published in the journal Neurology provides some encouraging news though, claiming the popular Alzheimer's drug donepezil may delay the progression of the disease in people suffering with mild cognitive impairment (MCI) or memory problems.

For the new study, researchers investigated 756 people with MCI between the ages of 55 and 91 for three years.

Of those, 208 were diagnosed with depression using a test that measures the severity and intensity of a person's depressive symptoms. For every one point increase on the test, a participant's risk of developing Alzheimer's disease went up by three percent.

Participants were also given either vitamin E, donepezil or a placebo pill.

Researchers found at 1.7 years into the study among depressed people with mild cognitive impairment, 11 per cent of those taking donepezil developed Alzheimer's disease compared to 25 percent of those who took vitamin E or placebo.

At 2.2 years, 14 per cent of those taking donepezil developed Alzheimer's compared to 29 per cent of those who took vitamin E or placebo.

The drug had little effect in the group of people who were not depressed.

Other news stories from 16/06/2009

Read more in the Zenopa News Archive

How this news is generated

Angela Robertson
QC/Training Consultant


Pharmaceutical Sales Jobs | Pharmaceutical Executive Jobs | Pharmaceutical Marketing Jobs | Medical Sales Jobs | Medical Devices Marketing Jobs | Medical Executive Jobs
Dental Sales Jobs | Veterinary Sales Jobs | Scientific Sales Jobs | Consumer Healthcare Sales Jobs | Consumer Healthcare Management Jobs | Medical Writing Jobs
Medical Writer Jobs | Healthcare PR Jobs | Animal Health Sales Jobs

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2012 Zenopa Ltd | terms & conditions of use